在IgA脏病中的药理干预:活体系统审查和网络元分析的协议
Soumita Bagchi1,2,3, Armando Teixeira-Pinto4,2, Nida Saleem4,2,5
1Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia soumita_bagchi@yahoo.co.in.
BMJ open
|August 27, 2025
概括
这项研究将对IgA脏病 (IgAN) 的药物治疗进行比较,IgA脏病是成年人最常见的脏病. 一个活网络的元分析将为Igan治疗的有效性和安全性提供持续的见解.
科学领域:
- 肝脏病学
- 临床流行病学
- 药理学
背景情况:
- 在成年人中,IgA脏病 (IgAN) 是最常见的原发性淋巴细胞疾病.
- 最近的进展导致IgAN治疗的多次成功临床试验.
- 需要确定可用的Igan药物干预措施的比较有效性.
研究的目的:
- 对IgAN进行药理干预的系统审查和网络元分析.
- 评估成年人使用IgAN治疗的相对有效性和安全性.
- 建立一个持续更新Igan治疗场景的活跃模型.
主要方法:
- 使用多个数据库进行RCT和准RCT的系统文献搜索.
- 独立的数据提取和偏差风险评估 (科克兰偏差风险2.0).
- 使用马尔科夫链蒙特卡洛方法的贝叶斯NMA,使用CINeMA/GRADE评估证据的确定性.
主要成果:
- 主要结局包括功能和死亡率.
- 二次性结局包括心血管疾病,不良事件和患者报告的结局.
- 结果将在同行评审的期刊上发表;本议定书中没有结果.
结论:
- 这种生活NMA将提供Igan治疗选择的持续概述.
- 这些发现将为IgAN管理提供基于证据的指南.
- 该方法旨在支持Igan的"生活指南"的设计.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
Nephrotic Syndrome II : Assessment and Medical Management
21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21
Nephrotic Syndrome III : Nursing Management
44
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
44
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


